NCT07228130 Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity Treatment
| NCT ID | NCT07228130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Miriam Hospital |
| Condition | Obesity & Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 275 participants |
| Start Date | 2026-01-07 |
| Primary Completion | 2029-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 275 participants in total. It began in 2026-01-07 with a primary completion date of 2029-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial is focused on testing dietary self-monitoring strategies used in behavioral obesity treatment. The goal is to determine which self-monitoring strategies are most useful for whom, at which points in treatment, and under what circumstances. Researchers will provide a 24-week online behavioral obesity treatment program, and will randomize participants to use one of 5 dietary self-monitoring strategies every two weeks. The five strategies include: recording all food and drink consumed and corresponding energy intake (i.e., "calories") on 7 days per week; recording all food and drink consumed and corresponding energy intake (i.e., "calories") on 3 days per week; self-monitoring of dietary lapses (i.e. any eating/drinking likely to cause weight gain or put weight loss at risk); smartwatch-based monitoring of energy intake (i.e., "calories"); and self-monitoring of body weight only via smart scale. Participants will: * Follow a 24-week online program for weight loss and health improvement * Use the assigned self-monitoring strategy every two weeks * Meet with the researchers periodically via online video call and provide research data by answering questions via periodic online surveys.
Eligibility Criteria
* English language fluent and literate at the 6th grade level * Body mass index (BMI) above 25 kg/m-squared * Able to walk 2 city blocks without stopping * Not currently participating in another weight loss program * Not currently taking weight loss medication * Has not lost ≥5% of body weight in the 6 months prior to enrolling * Has not been pregnant within the 6 months prior to enrolling * Does not plan to become pregnant within 12 months of enrolling * Denies having a heart condition, chest pain during periods of activity or rest, or loss of consciousness in the 12 months prior to enrolling * Denies any medical condition that would affect the safety of participating in unsupervised physical activity * Denies any condition that would result in inability to follow the study protocol, including terminal illness, substance abuse, eating disorder (not including Binge Eating Disorder) and untreated major psychiatric illness * Owns a smartphone compatible with study procedures and is willing to use it for study participation
Contact & Investigator
Graham Thomas, PhD
PRINCIPAL INVESTIGATOR
The Miriam Hospital
Frequently Asked Questions
Who can join the NCT07228130 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07228130 currently recruiting?
Yes, NCT07228130 is actively recruiting participants. Contact the research team at tech2trackstudy@brownhealth.org for enrollment information.
Where is the NCT07228130 trial being conducted?
This trial is being conducted at Providence, United States.
Who is sponsoring the NCT07228130 clinical trial?
NCT07228130 is sponsored by The Miriam Hospital. The principal investigator is Graham Thomas, PhD at The Miriam Hospital. The trial plans to enroll 275 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.